A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Milton S. Hershey Medical Center
Hoffmann-La Roche
Cambridge University Hospitals NHS Foundation Trust
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University Hospital, Gasthuisberg